ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), one of the world’s most prestigious meetings in genitourinary oncology, multiple landmark studies were presented that are reshaping clinical practice. Among them, advances in urothelial carcinoma (UC) stood out prominently.
EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

At the 2026 European Association of Urology (EAU) Annual Congress held in London, leading experts from around the world gathered to discuss the latest advances and evolving clinical practices in genitourinary oncology. During the meeting, Oncology Frontier had the privilege of interviewing Professor Fred Saad from the Centre Hospitalier de l’Université de Montréal, who shared key insights into his team’s latest research, major breakthroughs in prostate cancer, and future therapeutic directions.
EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xiaojun Huang: Haploidentical Hematopoietic Stem Cell Transplantation for Rare Diseases — Practice and Insights from the Beijing Protocol

EBMT 2026 China Voice | Professor Xiaojun Huang: Haploidentical Hematopoietic Stem Cell Transplantation for Rare Diseases — Practice and Insights from the Beijing Protocol

Over the past 15 years, the field of hematopoietic stem cell transplantation has undergone a profound transformation, largely driven by breakthroughs in haploidentical transplantation. Represented by the “Beijing Protocol” pioneered by Professor Xiaojun Huang and his team at Peking University People’s Hospital, haploidentical transplantation has not only overcome the long-standing limitation of donor availability but has also achieved outstanding outcomes in the treatment of hematologic malignancies, leading to its widespread adoption worldwide.
EBMT 2026 China Voice | Professor Jia Wei: A Powerful Combination Strategy Reshaping the Tumor Microenvironment and Opening a New Era of Durable Benefit in CAR-T Therapy

EBMT 2026 China Voice | Professor Jia Wei: A Powerful Combination Strategy Reshaping the Tumor Microenvironment and Opening a New Era of Durable Benefit in CAR-T Therapy

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. The congress gathered thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy, covering key topics such as optimization of transplant strategies, infection management, CAR-T therapy, and graft-versus-host disease (GVHD) management.
EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential academic events in the field, the congress brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease management.
ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.